Ehrlich Jason's Form 4 filing
Kodiak Sciences Inc.KOD · filed Dec 22, 2021
- Accession no.
- 0001209191-21-070934
- Filed
- Dec 22, 2021
- Trade date
- Dec 20, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $608.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ehrlich JasonCIK 0001754049 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | Common Stock | MOption exerciseAcquired | +6,950 | $10.29 | +$71,515.5 | 58,491 | Direct | |
| Dec 20, 2021 | Common Stock | SSaleDisposed | −1,532 | $86.60F2 | −$132,671.2 | 56,959 | Direct | |
| Dec 20, 2021 | Common Stock | SSaleDisposed | −3,709 | $87.60F3 | −$324,908.4 | 53,250 | Direct | |
| Dec 20, 2021 | Common Stock | SSaleDisposed | −1,709 | $88.51F4 | −$151,263.59 | 51,541 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | Common Stock | MOption exerciseDisposed | −6,950 | $0.00 | $0 | 225,488 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $86.085 to $87.025, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $87.06 to $88.035, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $88.13 to $89.01, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Medical Officer and Chief Development Officer